Danielle Brill
Stock Analyst at Truist Securities
(3.79)
# 728
Out of 5,044 analysts
88
Total ratings
43.42%
Success rate
12.06%
Average return
Main Sectors:
Stocks Rated by Danielle Brill
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $459 → $535 | $475.91 | +12.42% | 2 | Oct 17, 2025 | |
| IMVT Immunovant | Initiates: Hold | $16 | $21.98 | -27.21% | 5 | Oct 14, 2025 | |
| UPB Upstream Bio | Initiates: Buy | $47 | $24.84 | +89.21% | 1 | Oct 14, 2025 | |
| DNTH Dianthus Therapeutics | Initiates: Buy | $56 | $33.65 | +66.42% | 1 | Oct 14, 2025 | |
| PVLA Palvella Therapeutics | Maintains: Buy | $56 → $80 | $73.50 | +8.84% | 2 | Oct 2, 2025 | |
| VRTX Vertex Pharmaceuticals | Initiates: Market Perform | n/a | $422.39 | - | 3 | Sep 3, 2025 | |
| IRON Disc Medicine | Initiates: Buy | $86 | $87.61 | -1.84% | 6 | Jul 21, 2025 | |
| HRMY Harmony Biosciences Holdings | Initiates: Buy | $48 | $29.64 | +61.94% | 8 | Jul 21, 2025 | |
| TECX Tectonic Therapeutic | Initiates: Buy | $64 | $17.88 | +257.94% | 2 | Jul 21, 2025 | |
| NBIX Neurocrine Biosciences | Initiates: Buy | $163 | $147.38 | +10.60% | 6 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $66 | $64.50 | +2.33% | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $25.02 | +19.90% | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $19.17 | +25.20% | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $20 → $52 | $70.00 | -25.71% | 6 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $16.92 | - | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $79 | $53.49 | +47.69% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $18 | $13.16 | +36.78% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $150 | $24.22 | +519.32% | 3 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $149.13 | - | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Strong Buy | $605 | $836.39 | -27.67% | 7 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $22.62 | - | 5 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $50 | $42.53 | +17.56% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $51 | $43.43 | +17.43% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $180 → $100 | $7.66 | +1,205.48% | 5 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $67.49 | - | 9 | Sep 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $10.83 | - | 5 | Jun 27, 2023 |
Alnylam Pharmaceuticals
Oct 17, 2025
Maintains: Buy
Price Target: $459 → $535
Current: $475.91
Upside: +12.42%
Immunovant
Oct 14, 2025
Initiates: Hold
Price Target: $16
Current: $21.98
Upside: -27.21%
Upstream Bio
Oct 14, 2025
Initiates: Buy
Price Target: $47
Current: $24.84
Upside: +89.21%
Dianthus Therapeutics
Oct 14, 2025
Initiates: Buy
Price Target: $56
Current: $33.65
Upside: +66.42%
Palvella Therapeutics
Oct 2, 2025
Maintains: Buy
Price Target: $56 → $80
Current: $73.50
Upside: +8.84%
Vertex Pharmaceuticals
Sep 3, 2025
Initiates: Market Perform
Price Target: n/a
Current: $422.39
Upside: -
Disc Medicine
Jul 21, 2025
Initiates: Buy
Price Target: $86
Current: $87.61
Upside: -1.84%
Harmony Biosciences Holdings
Jul 21, 2025
Initiates: Buy
Price Target: $48
Current: $29.64
Upside: +61.94%
Tectonic Therapeutic
Jul 21, 2025
Initiates: Buy
Price Target: $64
Current: $17.88
Upside: +257.94%
Neurocrine Biosciences
Jul 21, 2025
Initiates: Buy
Price Target: $163
Current: $147.38
Upside: +10.60%
Jul 21, 2025
Initiates: Buy
Price Target: $66
Current: $64.50
Upside: +2.33%
Jul 21, 2025
Initiates: Buy
Price Target: $30
Current: $25.02
Upside: +19.90%
Jul 21, 2025
Initiates: Buy
Price Target: $24
Current: $19.17
Upside: +25.20%
Dec 10, 2024
Upgrades: Strong Buy
Price Target: $20 → $52
Current: $70.00
Upside: -25.71%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $16.92
Upside: -
Oct 10, 2024
Reinstates: Outperform
Price Target: $79
Current: $53.49
Upside: +47.69%
Oct 10, 2024
Reinstates: Outperform
Price Target: $18
Current: $13.16
Upside: +36.78%
Oct 10, 2024
Reinstates: Outperform
Price Target: $150
Current: $24.22
Upside: +519.32%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $149.13
Upside: -
Oct 10, 2024
Reinstates: Strong Buy
Price Target: $605
Current: $836.39
Upside: -27.67%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $22.62
Upside: -
Oct 10, 2024
Reinstates: Outperform
Price Target: $50
Current: $42.53
Upside: +17.56%
Oct 10, 2024
Reinstates: Outperform
Price Target: $51
Current: $43.43
Upside: +17.43%
Nov 14, 2023
Maintains: Outperform
Price Target: $180 → $100
Current: $7.66
Upside: +1,205.48%
Sep 18, 2023
Downgrades: Underperform
Price Target: n/a
Current: $67.49
Upside: -
Jun 27, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $10.83
Upside: -